Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Mapping intratumoral coverage of neural stem cell-delivered anti-HER2 antibody in breast cancer brain metastasis.

Created on 11 Nov 2026

Authors

Jawad Fares, Deepak Kanojia, Edgar Petrosyan, Alex L Tobias, Rafal Chojak, Atique U Ahmed, Irina V Balyasnikova, Maciej S Lesniak

Published in

Clinical & experimental metastasis. Volume 43. Issue 6. Nov 10, 2026. Epub Nov 10, 2026.

Abstract

Cell-based therapies can formulate and deliver biologics within the brain, but their development has relied largely on survival outcomes that do not distinguish inadequate payload potency from inadequate tumor distribution. We evaluated intratumoral coverage as a quantitative endpoint for cell-mediated delivery using neural stem cells (NSCs) engineered to secrete an anti-HER2 antibody in breast cancer brain metastasis. Intracranial HER2-positive BT474Br tumors received a single dose of 5 × 105 anti-HER2 antibody-secreting NSCs. Secreted human IgG was reconstructed across consecutive 10-µm sections spanning the entire tumor depth, and therapeutic activity of the same cell dose administered once was assessed in an independent survival experiment. A single NSC dose produced a mean section-level antibody coverage of 60.6%; coverage was ≥ 25% in 96.8% of sections and ≥ 50% in 74.2%. Coverage was greatest in the tumor core and declined toward both poles, a pattern consistent with carrier-cell localization limiting therapeutic reach. The same dose extended median survival from 67 days with vector-control NSCs to 73.5 days (P = 0.0009) and increased restricted mean survival by 10.8 days. These data provide an initial spatial benchmark for a therapeutically active dose and establish tumor coverage as a mechanistically informative endpoint for intracranial cell-based delivery.

PMID:
43007545
Bibliographic data and abstract were imported from PubMed on 11 Nov 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 12
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement